Gufic BioSciences Ltd

Gufic BioScience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gufic BioSciences Ltd

₹ 200 -4.69%
30 May - close price
gufic.com BSE: 509079 NSE : GUFICBIO
About

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Key Points

History[1]
Gufic was in the business of manufacturing and marketing injectable products since late 1970s. The group had earlier exited its API and formulations manufacturing division by selling its six major brands such as Mox (Amoxycillin) Injection, Zole (Miconazole Nitrate) etc. to Ranbaxy in 1997. The promoters then re-entered pharmaceutical formulations segment through incorporation of Gufic Biosciences Limited in 2000.
Gufic Biosciences has been manufacturing lyophilized injectables (their main business) for 40+ years. It started with small base of 50,000 vials back in 2007-08 to right now almost 4 million vials per month.

Website BSE NSE
  • Market Cap ₹ 1,942 Cr.
  • Current Price ₹ 200
  • High / Low ₹ 243 / 177
  • Stock P/E 24.4
  • Book Value ₹ 35.9
  • Dividend Yield 0.05 %
  • ROCE 22.6 %
  • ROE 25.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has delivered good profit growth of 38.6% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 32.3%
  • Company's median sales growth is 22.5% of last 10 years

Cons

  • Company might be capitalizing the interest cost
  • Working capital days have increased from 91.2 days to 136 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
87 54 128 167 132 251 194 172 162 165 175 177 173
75 55 99 139 108 205 158 139 130 132 142 143 141
Operating Profit 12 -1 29 27 24 46 36 33 33 33 33 34 32
OPM % 14% -1% 23% 16% 18% 18% 18% 19% 20% 20% 19% 19% 19%
1 1 2 0 1 1 0 2 0 0 1 1 1
Interest 4 3 4 4 3 1 2 1 1 1 2 2 3
Depreciation 4 2 5 3 4 4 4 4 5 4 5 6 6
Profit before tax 6 -5 23 20 17 42 30 29 26 28 27 27 24
Tax % 21% 27% 25% 24% 25% 25% 23% 27% 23% 26% 26% 25% 24%
Net Profit 5 -4 17 15 13 31 23 21 20 21 20 20 18
EPS in Rs 0.64 -0.48 2.23 1.99 1.65 3.22 2.41 2.17 2.09 2.17 2.08 2.10 1.87
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
81 98 121 148 201 245 306 351 379 488 779 691
74 87 109 134 181 222 267 305 327 404 633 556
Operating Profit 7 11 12 14 20 23 39 46 52 84 146 135
OPM % 9% 11% 10% 10% 10% 9% 13% 13% 14% 17% 19% 20%
0 0 1 1 1 1 4 4 6 4 3 3
Interest 3 4 4 4 6 6 9 10 14 14 5 8
Depreciation 2 2 2 4 4 4 4 5 14 16 17 22
Profit before tax 3 5 6 7 10 14 30 35 30 58 127 107
Tax % 49% 37% 32% 36% 29% 37% 45% 38% 25% 23% 24% 25%
Net Profit 2 3 4 4 7 9 16 22 23 44 96 80
EPS in Rs 0.20 0.43 0.55 0.54 0.95 1.17 2.13 2.82 2.92 5.68 9.89 8.22
Dividend Payout % 25% 12% 9% 9% 5% 4% 2% 2% 2% 2% 1% 1%
Compounded Sales Growth
10 Years: 22%
5 Years: 18%
3 Years: 22%
TTM: -11%
Compounded Profit Growth
10 Years: 37%
5 Years: 39%
3 Years: 52%
TTM: -17%
Stock Price CAGR
10 Years: 43%
5 Years: 8%
3 Years: 56%
1 Year: -12%
Return on Equity
10 Years: 30%
5 Years: 31%
3 Years: 32%
Last Year: 26%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
8 8 8 8 8 8 8 8 10 10 10 10
Reserves 12 15 18 19 26 30 46 68 120 164 259 338
20 35 33 33 43 57 80 98 126 62 64 334
34 32 52 67 75 84 104 106 152 157 188 179
Total Liabilities 74 90 111 127 152 178 238 280 408 392 521 861
18 27 30 25 22 22 23 24 83 100 115 160
CWIP 1 3 0 0 0 0 2 10 31 13 41 170
Investments 0 0 0 0 0 0 0 0 0 0 0 1
55 60 81 102 130 156 213 245 294 279 365 531
Total Assets 74 90 111 127 152 178 238 280 408 392 521 861

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
5 5 11 11 -4 -4 -5 5 47 87 104
-3 -13 -3 -2 -1 -5 -9 -13 -43 -7 -96
-2 8 -7 -5 5 7 14 8 -4 -79 -3
Net Cash Flow 0 0 1 4 -0 -1 1 -0 0 2 5

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 101 75 85 82 102 78 97 107 103 93 71 109
Inventory Days 137 143 144 165 180 190 238 190 249 138 102 202
Days Payable 180 144 176 223 188 132 192 157 238 162 125 143
Cash Conversion Cycle 58 74 54 25 94 136 143 141 114 69 48 167
Working Capital Days 82 71 64 48 76 84 109 128 110 80 58 136
ROCE % 15% 18% 17% 18% 24% 24% 33% 30% 21% 29% 46% 23%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
65.75 65.75 65.75 65.75 65.13 75.48 75.48 75.48 75.00 75.00 75.00 75.00
0.59 0.06 0.33 0.23 0.14 1.52 1.69 1.51 1.38 0.06 0.16 0.72
7.99 8.73 8.71 8.24 3.24 2.13 1.19 1.12 1.13 1.16 1.16 1.16
25.67 25.46 25.21 25.77 31.49 20.87 21.64 21.89 22.49 23.76 23.67 23.12

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls